Bio Asia 2016- Connecting dots

BioAsia 2016, the international life sciences convention, which is 3 day event is being held from 8-10th February,2016 at HICC, Hyderabad. The thirteenth edition of the prestigious event is organized by the Industries and Commerce Department in partnership with Government of India, Federation of Asian Biotech Associations (FABA) and Pharmaceutical Export Promotion Council (Pharmexcil). The event showcases products like to further boost the growth for life sciences Industry.

The Government of India has envisioned a Digital India and has been working towards building smart cities using the latest technology. The use of technological interventions has also been in use for extensive development in the healthcare sector. In terms of health, India has a rich pool of patient and disease information, which, if profiled can open up infinite opportunities of finding breakthrough and affordable healthcare solutions.

There is an increasing pressure to reduce healthcare costs globally, emerging markets particularly India is gaining further prominence with its scientific and tech talent pool, contract research and manufacturing activities, process reengineering and innovative R&D capabilities serving as key enablers. Under this backdrop, the 13th BioAsia will focus on connecting the dots to build stakeholder consensus and draw distinct roadmap.

The BioAsia 2016 is a raised area which will focus on Digital Health and mHealth among others with the objective of providing a platform to enable cross pollination of ideas between tech companies, medical community, life sciences organizations and the startup community. This event is considered to be the state’s flagship international convention.

BioAsia, over the years, has built a formidable reputation with the key stakeholders and is now considered one of the pre-eminent meetings in Asia witnessing participation of about 1700 delegates and 2000 visitors from over 50 Countries every year comprising investors, pharma & Biotech companies, Clinicians and Medical Praticitioners, Hospitals & Telemedicine experts, Tech companies, Big Data Analysts, App development and entrepreneurs, Channel partners & Delivery consultants, Academia & Scientists and Venture Capitalists & PE firms.

As a part of 2016 event, they are planning to organize a start-up pavilion to promote and showcase India’s vibrant start up community to the global audience. This year the event is going to focus on 500+ startups relating to healthcare and the announcement of Startup India initiative, India is all set to capitalize on the next big global opportunity in health care. The main focus of the event will be on –

• mHealth & diagnostic mobile apps
• Patient data management and eHealth records
• 3D prosthetics & 3D Bioprinting
• Personalized medicine & treatments & many more…

Advantage India
The Indian life sciences industry is on the threshold of entering a New Era of growth and positivity, promising extraordinary growth and an innovation driven bio-economy. The Indian biotechnology sector is one of the fastest growing knowledge based sectors in India and is expected to play a key role in shaping India’s rapidly developing economy. With numerous comparative advantages in terms of R&D facilities, knowledge skills and cost effectiveness, the biotechnology industry in India is fast emerging as a Global Leader.

Alluring India

• Leading the world: India is among the top six producers of pharmaceuticals in the world
• World Renowned Quality: Approx. 1,297 WHO GMP standard manufacturing units.
• A Pharma Hub: Over 10,500 manufacturing units & over 3,000 pharma companies growing at an exceptional rate.
• Affordable Quality: Manufacturing costs are approx. 35-40% of those in the US due to low installation & manufacturing costs.
• Growing Capabilities: Large pool of scientific talent at a reasonable cost
• Dedicated to Excellence: 19 dedicated pharmaceutical SEZs at various stages

Advantage Hyderabad

• Front Runner in Life Science Innovation and Manufacturing in the Country.
• About 33% of the vaccines produced globally are from Hyderabad.
• Inherent strengths in basic and advanced sciences (including chemistry, biology, IT, etc.), concentration of activities across verticals, and disease profile enables seamless forward and backward linkages / integration for product development including clinical development and translational research.
• Availability of ready to occupy facilities in various sizes with common facilities and large bank of land.
• High quality ecosystem with rich talent pool puts Hyderabad ahead
• Life Sciences Hub – Conducive Ecosystem
• Bio-Tech: Houses India’s largest and only systematically developed biotech cluster – the Genome Valley
• Pharma: Pharma Capital of India -Accounts for about 35-40% of India’s pharma production
• Bio-Agri: Seed Capital of India - Houses Country’s first translational platform
• Medi Tech: India’s first Medical Devices Park with common facilities and incubation services
• Services: Significant number of CROs/CMOs, vivarium, and testing laboratories easing the outsourcing

G.Rajendera Kumar